Результаты поиска

Выявляется высокий уровень использования медицинских услуг после операции на шейном позвоночнике с использованием комплексных методов прогнозирования.

Расходы на медицинское обслуживание пациентов с хроническими заболеваниями позвоночника и пациентов, проходящих хирургическую операцию, продолжают расти заметными темпами. Таким образом, выявление пациентов, подверженных риску в плане более широкого использования послеоперационного медицинского обслуживания, имеет решающее значение для оптимизации результатов медицинского обслуживания и распределения ресурсов. Цель нашего исследования заключается в использовании целого ряда предоперабельных характеристик пациентов, включая всеобъемлющую медицинскую, хирургическую и социальную историю, для разр

Совпадение в полном тексте источника
… halazepam”, “lorazepam”, “oxazepam”, “prazepam”, “quazepam”, “temazepam”, “triazolam” | Immunosuppressants | “mycophenolate”, “etanercept”, “adalimumab”, “azathioprine”, “cyclosporine”, “tacrolimus”, “sirolimus”, “infliximab”, “natalizumab”, “methotrexate”, “certolizumab”, “prednisone”, “dexamethasone”, “cortisone …

Неудовлетворенные потребности в уходе за пациентами, страдающими расстройством спектра нейромиэлита и миелином олигодендроцитом гликопротеиновым заболеванием, связанным с антителами: знания из Германии.

:: Нейромиелитное расстройство спектра (NMOSD) и миелин олигодендроциты гликпротеиновые заболевания, связанные с антителами (MOGAD), являются редкими аутоиммунными расстройствами. Их реальная распространенность в Германии неизвестна и может быть оценена только на основе разнородных международных данных. Предположим 1-3 Число случаев 100,000 люди для каждой болезни предполагают несколько thousand В то же время в регистре немецкой Исследовательской группы по нейромиэлиту (НЕМОС) в настоящее время имеются данные лишь о том, что 1,300 - пациентов, которых видели в специализированных центрах. Число

Совпадение в полном тексте источника
… Bars represent absolute numbers of responses (of N = 56 respondents), with each colour representing a different drug: Cortisone, Azathioprine, Mycophenolate Mofetil, IVIG, Rituximab, Inebilizumab, Eculizumab, Ravulizumab, Tocilizumab, and Satralizumab (see legend). …

:: Анализ тенденций в области выявления множественных склерозов и анализа терапевтических тенденций на основе графиков знаний: реальные данные, полученные с помощью two - крупные системы здравоохранения.

Площадь склероза (MS) эволюционировала со временем. Мы провели основанный на использовании графиков анализ тенденций, связанных с рецептурной терапией, направленной на модификацию конкретных заболеваний (ДМТ), с использованием продольных реальных клинических данных. Мы проанализировали связанные с реестром данные электронной медицинской записи (ЭЗ) two между крупными независимыми системами здравоохранения 2004 и 2022, включая как академическую, так и общинную практику. Мы разработали неконтролируемый фенотификационный алгоритм, который использует общедоступный график знаний и информативные эле

Совпадение в полном тексте источника
… Finally, steroids ( e.g., cortisone, methylprednisolone, and prednisolone) were frequently used in the management of acute MS relapses and were included as references. …

Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy.

Introduction: This paper describes the peculiarities of the plasma-derived medicinal product (PDMP) market and illustrates the results of a review of the literature on policies aimed at counteracting the shortage of PDMPs. Characteristics of PDMPs: Plasma is primarily used for the industrial production of blood products (80%). The demand for PDMPs, particularly immunoglobulins (IGs), is increasing. However, the production of PDMPs is complex, long (7-12 months), and expensive, accounting, according to US estimates, for 57% of the total costs of PDMPs compared to 14% for small molecules. PDMP m

Совпадение в полном тексте источника
… ➢ In the initial stages of myasthenia gravis, when the effects of cortisone and/or immunosuppressive therapy are anticipated. ➢ As preparation for thymectomy, in patients with myasthenia gravis. …

Innovative Approaches in Knee Osteoarthritis Treatment: A Comprehensive Review of Bone Marrow-Derived Products.

Knee osteoarthritis (OA) is a chronic articular disease characterized by the progressive degeneration of cartilage and bone tissue, leading to the appearance of subchondral cysts, osteophyte formation, and synovial inflammation. Conventional treatments consist of non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and glucocorticoids. However, the prolonged use of these drugs causes adverse effects. NSAIDs, for instance, are known to be nephrotoxic, increasing the damage to articular cartilage. New therapies capable of accelerating the process of tissue regeneration and repair are bein

Совпадение в полном тексте источника
… Comparative studies of BMA versus cortisone for glenohumeral joint OA treatment showed significant improvements in pain and function for the BMA group, though limited differences were observed in certain outcome scores [ 44 ]. …

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.

Primary central nervous system lymphoma (PCNSL) is a rare and frequently fatal lymphoma subtype. The programmed death-1 (PD-1) pathway has emerged as a potential therapeutic target, but the effectiveness of PD-1 antibody sintilimab in combination with immunochemotherapy as a frontline treatment for PCNSL remains to be determined. In this phase 2 trial (ChiCTR1900027433) with a safety run-in, we included patients aged 18-70 with newly diagnosed PCNSL. Participants underwent six 21-day cycles of a SMTR regimen, which includes sintilimab (200 mg, Day 0), rituximab (375 mg/m2, Day 0), methotrexate

Совпадение в полном тексте источника
… Notably, the administration of cortisone to some patients due to AEs poses challenges to the accurate assessment of treatment response. This introduces a potential confounding factor that needs careful consideration when interpreting our results. …

Педиатрическое ожирение - долгосрочные последствия и последствия потери веса.

Согласно ВОЗ, детский ожирение - это one наиболее серьезных проблем, с которыми сталкивается 21st Столетие. Более 100 million Сегодня у детей ожирение. Уже в детстве почти все органы подвергаются риску ожирения. В этом обзоре мы представляем текущие знания о болезнях, связанных с детским ожирением, и о том, как они влияют на потерю веса. One Основным побудительным фактором является вызванное ожирением низкосортное хроническое воспаление, которое уже наблюдается у детей дошкольного возраста. Это воспаление в сочетании с эндокринным, паракринным и метаболическим воздействием ожирения повышает до

Совпадение в полном тексте источника
… Another important key player is cortisone, which is converted to cortisol by means of the enzyme 11‐β‐HSD in several tissues. Increased total body adipose tissue will result in enhanced conversion and thereby higher bioavailability of cortisol, which also affects the immune system [ 18 , 19 ]. …

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020.

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference-held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)-after the newest recommendations (2020) on MRONJ were published by two s

Совпадение в полном тексте источника
… . (#4) Performing extractive procedures without removing, even if necessary, the alveolar bone, and plan the healing as a second intention (especially with cortisone administration). 2.4.2. …

Agaricus blazei-Based Mushroom Extract Supplementation to Birch Allergic Blood Donors: A Randomized Clinical Trial.

Since Agaricus blazei Murill (AbM) extract reduced specific IgE and ameliorated a skewed Th1/Th2 balance in a mouse allergy model, it was tested in blood donors with self-reported, IgE-positive, birch pollen allergy and/or asthma. Sixty recruited donors were randomized in a placebo-controlled, double-blinded study with pre-seasonal, 7-week, oral supplementation with the AbM-based extract AndosanTM. Before and after the pollen season, questionnaires were answered for allergic rhino-conjunctivitis, asthma, and medication; serum IgE was measured, and Bet v 1-induced basophil activation was determ

Совпадение в полном тексте источника
… Criteria of exclusion were undergoing or planning to undergo allergen immune therapy (AIT), anti-IgE therapy, or cortisone injection. Twenty-nine donors were randomized stochastically to Andosan TM intervention and 31 were randomized to placebo intervention ( Figure 1 ). …

Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published Literature.

Allogeneic hematopoietic stem cell transplantation (SCT) is often the only curative option for many patients with malignant and benign hematological stem cell disorders. However, some issues are still of concern regarding finding a donor like shrinking family sizes in many societies, underrepresentation of the ethnic minorities in the registries, genetic variability for some races, and significant delays in obtaining stem cells after starting the search. So there is a considerable need to develop alternate donor stem cell sources. The rapid and near universal availability of the haploidentical

Совпадение в полном тексте источника
… Prevention of cyclophosphamide-induced tolerance to erythrocytes by pretreatment with cortisone Proceedings of the Society for Experimental Biology and Medicine 1970 133 1 280 285 10.3181/00379727-133-34456 2-s2.0-0014703355 5412347 20 Nishimura Y. Mayumi H. Tomita Y. Eto M. Maeda T. Nomoto K. …

Концептуализация комплексного ухода за многими миеломами: роль питания, дополнительных услуг и дополнительных услуг.

Множественная миелома (ММ) — вторая по распространенности гематологическая гелингология, масштабы которой в последние годы значительно возросли. Прогноз ММ радикально изменился с введением новых лекарственных средств, повышающих ожидаемую продолжительность жизни; рецидивы являются обычным явлением во время болезни и характеризуются увеличением числа отказов от лечения. Кроме того, пациенты ММ сталкиваются с проблемами, связанными с качеством жизни, в то время как обычное лечение может быть ограничено. Это включает боль в костях и диализ из-за осложнений острой почечной недостаточности. Поэтому

Совпадение в полном тексте источника
… These data are exciting considering that in MM, we often use therapeutic regimens, if effective, up to progression; if these medications, as often happens, contain cortisone, the patient is frequently subjected to massive and prolonged doses of steroids and their heavy long-term side effects. …

Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.

Over the past 40 years, the 5-years-overall survival rate of pediatric cancer reached 75-80%, and for acute lymphoblastic leukemia (ALL), exceeded 90%. Leukemia continues to be a major cause of mortality and morbidity for specific patient populations, including infants, adolescents, and patients with high-risk genetic abnormalities. The future of leukemia treatment needs to count better on molecular therapies as well as immune and cellular therapy. Advances in the scientific interface have led naturally to advances in the treatment of childhood cancer. These discoveries have involved the recog

Совпадение в полном тексте источника
… However, for this type of patient who is identified as being high-risk (cortisone resistant, multiple relapses), but without a targetable genetic profile, immunotherapy remains a suitable solution, as demonstrated by the most recent studies. …

Rethinking corticosteroids use in oncology.

Corticosteroids (CSs), widely used in oncology for their anti-inflammatory and immunosuppressive properties, help manage cancer-related symptoms and side effects. However, their long-term use may negatively affect patient survival and exacerbate tumor progression. Elevated glucose and glutamine metabolism, disruption of vitamin D levels, and alterations in the microbiome are some of the key factors contributing to these adverse outcomes. Approaches such as ketogenic diets, fasting, sartans, and vitamin D supplementation have shown promise in providing similar benefits to CSs while mitigating t

Совпадение в полном тексте источника
… Use of pituitary adrenocorticotropic hormone (ACTH) and cortisone in lymphomas and leukemias. J. Am. Med. Assoc. 144 (16), 1349–1353. 10.1001/jama.1950.02920160023005 Petrelli F., Bukovec R., Perego G., Luisa R., Luciani A., Zaniboni A., et al. (2020). …

CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?

Chimeric antigen receptor (CAR) T-cell systemic immunotherapy has revolutionized how clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar mechanism of action, CAR T-cell-based therapy has enlarged the spectrum of neurological toxicities. CAR T-cell-associated neurotoxicity-initially defined as CAR T-cell-related encephalopathy syndrome (CRES) and currently coined within the acronym ICANS (immune effector cell-associated neurotoxicity syndrome)-is perhaps the most concerning toxicity of CAR T-cell therapy. Importantly, hematologic malignancies (especial

Совпадение в полном тексте источника
… Finally, intrathecal treatment with cortisone, cytarabine, and methotrexate can serve as a possibility in steroid-refractory ICANS ( 3 ). 3. CNS involvement in lymphoma, leukemia, and myeloma 3.1. …

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.

Multiple myeloma (MM), the second most common hematologic malignancy, is characterized by the clonal expansion of plasma cells. Despite dramatic improvements in patients' survival over the past decade due to advances in therapy exploiting novel molecular targets (immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies), the treatment of relapsed and refractory disease remains challenging. Recent studies confirmed complex, dynamic, and heterogeneous genomic alterations without unifying gene mutations in MM patients. In the current review, we survey recent therapeutic strategies,

Совпадение в полном тексте источника
… Bortezomib was superior to cortisone therapy, showing higher response rates (43% vs. 9%) and longer overall survival (29.8 vs. 23.7 months) [ 39 ]. This led to the approval of bortezomib in the USA in 2005 in the second-line treatment of MM patients. …

Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement.

The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, the number of patients diagnosed with cardiac amyloidosis has increased significantly recently due to growing awareness of the disease, improved diagnostic capabilities and demographic trends. Specific therapies that improve patient prognosis have become available for certain types of cardiac amyloidosis. Thus, the earliest possible referral of patients with suspicion of cardiac amyloidosis to an experienced center is crucial to ensure rapid diagnosis, early initiation of treatmen

Совпадение в полном тексте источника
… from the recommendations of the German Cardiac Society [ 143 ]) CMR cardiac magnetic resonance imaging, LGE late gadolinium enhancement, ECG electrocardiogram, NT-proBNP N-terminal brain natriuretic peptide a Assessment of NT-proBNP performed when patient is in cardiac compensation, some time after cortisone …

New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil.

The use of already-approved drugs to treat new or alternative diseases has proved to be beneficial in medicine, because it reduces both drug development costs and timelines. Most drugs can be used to treat different illnesses, due their mechanisms of action are not restricted to one molecular target, organ or illness. Diverging from its original intent offers an opportunity to repurpose previously approved drugs to treat other ailments. This is the case of sildenafil (Viagra), a phosphodiesterase-5 (PDE5) inhibitor, which was originally designed to treat systemic hypertension and angina but is

Совпадение в полном тексте источника
… AZD4017 effect over IIH is explained because its molecular mechanism of action; as an oral selective competitive inhibitor of the intracellular enzyme 11β-HSD, AZD4017 prevents the conversion of cortisone to active cortisol, reducing intracranial pressure ( 8 ). …

Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.

Classical Hodgkin's lymphoma (cHL) is a B-cell malignancy comprised of pathologic Reed Sternberg cells with a surrounding immune-tolerant inflammatory milieu. RS cells evade immune recognition in part through programmed death ligand 1 (PD-L1) overexpression, which is genetically programmed through copy number alterations, polysomy, and amplification of the 9p24.1 locus encoding PD-L1. By engaging with PD-1+ T-cells, PD-L1 delivers a potent immune suppressive signal promoting immunologic escape of the tumor cell. Enhancing antitumor immune response by targeting PD-1 with the monoclonal antibody

Совпадение в полном тексте источника
… patients experiencing grade 3 toxicity, but no grade 4 toxicity or toxicity leading to discontinuation of treatment reported. 111 An increased incidence of infusion reactions were noted with BV and nivolumab when the 2 drugs were administered together, but this was improved with the addition of hydro-cortisone …

Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.

The majority of breast cancers are driven by oestrogen receptor-α (ERα) activation, and endocrine therapy represents the mainstay treatment for these patients1. However, resistance is common and tumours often progress after years of endocrine suppression2. Periodic fasting enhances the efficacy of standard endocrine therapy and delays acquired drug resistance, although the underlying mechanisms remain unclear3. Here we show that fasting induces extensive epigenetic reprogramming in ERα-positive breast cancer xenografts when combined with endocrine therapy, with large-scale activation of glucoc

Совпадение в полном тексте источника
… ELISA assays to detect mouse serum levels of cortisone and progesterone were purchased from R&D System and ALPCO respectively while ELISA assays to detect human serum levels of cortisol and progesterone were purchased from R&D System and Enzo, respectively. …

Abstracts of the 5(th) Cachexia Conference, Barcelona, Spain, December 5-8, 2009.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.